Clinical Trials

  • SY-1365 is an investigational drug that stops the function of a protein known as CDK7. Previous workhas shown that CDK7 is necessary for some cancers to grow. Therefore, SY-1365 could be used to slow down the growth of cancer. This research study is being done to understand the highest tolerated dose of SY-1365, and to assess the safety of SY-1365 in patients with advanced solid tumors where standard therapies are no longer effective or do not exist. "Investigational" means that SY-1365 has not been approved by the United States Food and Drug Administration (FDA).
  • We are doing this study to find out if tisotumab vedotin treats ovarian cancer. We want to see if patients with your kind of ovarian cancer respond to the drug. We want to see how long it takes patients to respond to tisotumab vedotin and how long the response lasts. We also want to learn more about any side effects patients have when they get tisotumab vedotin.Tisotumab vedotin is a type of drug called an antibody drug conjugate or ADC. ADCs usually have 2 parts. Antibody: Antibodies are part of your immune system. Usually, they help protect you from getting sick.
  • The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system attack and destroy the cancer cells.
  • This study is being done to determine if adding the investigational drugs (TSR-042 and niraparib) to standard of care treatment delays or prevents ovarian cancer recurrence (prevents the ovarian cancer from coming back).
  • The purpose of this study is to see how well an investigational new drug and study device combination work to treat women with pre-cancerous cells of the vulva caused by human papillomavirus (HPV) and,thereby avoid surgery. To participate in this study you must have high grade squamous intraepithelial lesion (HSIL) of the vulva caused by HPV types 16 or 18.
  • When women have a cesarean delivery, there is an amount of bleeding. Occasionally (in less than 5 of every 100 births) there is severe bleeding that can place the mothers health at risk. When there is too much bleeding after a cesarean delivery, women are given medicines, blood transfusions, or possibly need another surgery. Tranexamic acid is routinely used to lessen the chance of hemorrhage. It works by making your blood clot sooner. It is not routinely used for cesarean sections. We are doing this study to see if this drug also works for women who are having a cesarean section.
  • The purpose of this study, which involves research, is being done to see how well an investigational new drug and study device combination will work to treat people with pre-cancerous cells on the cervix caused by human papillomavirus (HPV). The treatment combination is testing a drug, called VGX-3100, given by injection and used with the study device, CELLECTRA 5PSP, that delivers a small electric charge through 5 needles to increase the amount of the study drug taken up by muscle.
  • We are asking you to participate in this research study because you are a woman of child-bearing age or potential and interested in using an intrauterine device (IUD) for birth control for up to 5 years.